Influence of Antiseptic Agents on Interleukin-8 Release and Transmigration of Polymorphonuclear Neutrophils in a Human<i>In Vitro</i>Model of Peritonitis

Sendt, Wolfgang; Mansouri, Erfan; Schmitt‐Graeff, Annette; Wolff-Vorbeck, Guido; Schöffel, U.

doi:10.1089/109629602761624199

Cited by 5 publications

(1 citation statement)

References 26 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taurolidine has also been shown to modulate immunoregulatory properties of immune cells through its taurine moiety. It inhibits the production of the pro-inflammatory cytokines Interleukin (IL)-1 and Tumor Necrosis Factor α (TNFα) by peripheral blood mononuclear cells (PBMCs), and IL-6 and IL-8 by peritoneal and hepatic cells, respectively (12)(13)(14)(15)(16). Decreased toxicity through the binding of taurolidine to microbial endotoxins has also been reported (1,17).…”

Section: Taurolidinementioning

confidence: 99%

The Antiseptic and Antineoplastic Agent Taurolidine Modulates Key Leukocyte Functions

Wouters

MENNEN

Morsche

et al. 2022

In Vivo

View full text Add to dashboard Cite

Background/Aim: Although taurolidine is known to exert a wide spectrum of biological actions, its effects on immune cells have not been characterized in detail. In this study, we investigated the ex vivo effects of taurolidine on relevant innate and adaptive immune cell functions. Materials and Methods: Leukocyte functions in whole blood were assessed following treatment with various taurolidine concentrations. Viability of peripheral blood mononuclear cells (PBMCs) and granulocytes was measured using the WST-1 assay. PBMC function was assessed by measuring TNFα and IFNγ production after stimulation with lipopolysaccharide (LPS) or Candida, respectively. Reactive oxygen species (ROS) production by granulocytes was measured in whole blood using luminolenhanced chemiluminescence. Granulocyte degranulation and activation were evaluated by membrane expression of degranulation (CD63, CD66B) and adhesion markers (CD62L, CD11b) using immunofluorescent staining followed by flowcytometric analysis. Results: Taurolidine decreased viability of PBMCs and granulocytes: after 2 h, IC 50 concentrations were 500 and 520 μg/ml, respectively. Following prolonged exposure (≥24 h) of PBMCs, the IC 50 concentrations declined to 40 μg/ml. PBMC cytokine production significantly decreased at taurolidine concentrations below the cytotoxic threshold, whereas no changes in ROS production were observed. The expression of all granulocyte adhesion and degranulation markers increased at concentrations higher than 500 μg/ml (the cytotoxic level of taurolidine). Conclusion: Taurolidine exhibits a dose-and timedependent cytotoxicity toward PBMCs and granulocytes. The effects on PBMCs, as exemplified by a decrease in cytokine production, occurred below the toxic threshold, whereas granulocyte function (ROS production) remained unchanged at these taurolidine concentrations. Granulocyte activation and degranulation markers only increased at cytotoxic taurolidine concentrations.

show abstract

Section: Taurolidinementioning

confidence: 99%

The Antiseptic and Antineoplastic Agent Taurolidine Modulates Key Leukocyte Functions

Wouters

MENNEN

Morsche

et al. 2022

In Vivo

View full text Add to dashboard Cite

show abstract

Novel Molecular Mechanism to Account for Action of Taurine Against Testicular Ischemia-Reperfusion Injury

Namazi

2008

Urology

View full text Add to dashboard Cite

Oral Administration of Taurolidine Ameliorates Chronic DSS Colitis in Mice

Chromik

Müller

Albrecht

et al. 2007

Journal of Investigative Surgery

View full text Add to dashboard Cite

Taurolidine (TRD) has antimicrobial and anti-inflammatory properties. However, the anti-inflammatory effects of TRD in inflammatory bowel diseases (IBD) have not been investigated. Here, we have analyzed the toxicity of TRD after oral long-term application in mice and examined the impact of oral TRD in a dextran sulfate sodium (DSS) model of experimental colitis. Female C57/BL6 mice received TRD in various concentrations (0.1% to 0.4%) for 60 days. Toxicity was evaluated by use of a disease activity index (DAI) and histological examination of major metabolic organs. Furthermore, the impact of 0.2% TRD on a chronic DSS colitis was examined by daily DAI, histological crypt damage score (CDS), bacterial translocation into mesenteric lymph nodes (MLN), and colonic expression of tumor necrosis factor (TNF) alpha, transforming growth factor (TGF) beta, interleukin (IL)-1beta, IL-6, cytochrome oxidase (COX)-2, and monocyte chemotactic protein (MCP)-1 by real-time polymerase chain reaction (PCR). Oral TRD administration for 60 days was well tolerated by the animals and did not show any toxic effects in terms of DAI and histological changes. TRD treatment of DSS colitis led to increased survival of 100%, compared to 33% in the untreated colitis group (p < or = .005). Clinical amelioration was mirrored by significantly reduced DAI and CDS in the TRD treated colitis. Colonic cytokine expression and bacterial translocation into MLN showed no differences between both groups. We thus report for the first time that oral application of TRD results in amelioration of an experimental IBD model. We hypothesize direct intraluminal antimicrobial effects of TRD as well as anti-inflammatory effects during the acute phase of DSS colitis.

show abstract

Influence of Antiseptic Agents on Interleukin-8 Release and Transmigration of Polymorphonuclear Neutrophils in a HumanIn VitroModel of Peritonitis

Abstract: The diminished IL-8 response together with low PMN transmigration rates after addition of TAU and POLY may reflect either antiinflammatory effects or cellular damage.

Cited by 5 publications

References 26 publications

The Antiseptic and Antineoplastic Agent Taurolidine Modulates Key Leukocyte Functions

The Antiseptic and Antineoplastic Agent Taurolidine Modulates Key Leukocyte Functions

Novel Molecular Mechanism to Account for Action of Taurine Against Testicular Ischemia-Reperfusion Injury

Oral Administration of Taurolidine Ameliorates Chronic DSS Colitis in Mice

Contact Info

Product

Resources

About